Orion Oyj B Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Wed, Feb 17, 2027, after the market closes · estimates and history
Orion Oyj B Forecast
Orion Oyj B short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 21.7% a year, a typical one-standard-deviation range is 97.34–103.46 over a week, 94.12–106.68 over a month and 78.65–122.15 over a year. (Signals as of 22 Nov 2026.)
Orion Oyj B Price Chart
Orion Oyj B Factors
YoY −20.6%
YoY +24.8%
YoY +21.6%
YoY −21.5%
YoY +23.4%
YoY +6.9%
YoY +26.0%
YoY +66.9%
YoY −121.6%
YoY −110.3%
YoY +36.6%
YoY +35.9%
YoY −70.6%
YoY +40.0%
YoY +78.2%
Orion Oyj B fundamentals: income statement, balance sheet & cash flow
Orion Oyj B reported revenue of €1.89bn and net income of €500.3m in FY2025, the year ended 31 December 2025 — revenue up 22.5% and net income up 51.7% on the prior year. Free cash flow was €219.2m. These figures are as reported in the filings, not restated: 26 fiscal years and 89 quarters of history, back to December 2000.
| EUR millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 1,889.5 | 1,542.4 | 1,189.6 | 1,340.7 | 1,041.0 |
| Cost of revenue | 676.5 | 596.0 | 531.9 | 491.7 | 447.5 |
| Gross profit | 1,213.0 | 946.4 | 657.7 | 849.0 | 593.5 |
| Research & development | 210.4 | 179.6 | 126.9 | 135.8 | 117.7 |
| Selling, general & admin. | — | 350.2 | 256.0 | — | — |
| Operating income | 625.0 | 416.6 | 274.9 | 439.6 | 243.3 |
| EBITDA | 681.7 | 513.5 | 328.2 | 489.6 | 289.4 |
| Interest expense | 8.7 | 8.4 | 5.7 | 1.8 | 1.3 |
| Pre-tax income | 627.8 | 413.1 | 271.9 | 440.3 | 242.3 |
| Income tax | 127.5 | 83.2 | 55.1 | 90.8 | 48.5 |
| Net income | 500.3 | 329.9 | 216.8 | 349.5 | 193.8 |
Download Orion Oyj B fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ORNBV.HE&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Orion Oyj B
Explore MacroFinance macro & markets research and analysis.
Orion Oyj B Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Orion Oyj B; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Orion Oyj B’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Orion Oyj B (Finland)
Orion Oyj B is a listed security in Finland. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Orion Oyj B?
What is the latest Orion Oyj B price?
Is Orion Oyj B in an uptrend?
How volatile is Orion Oyj B?
What factors affect Orion Oyj B?
Which trading strategies trade Orion Oyj B?
How are Orion Oyj B returns analysed?
Where can I download free Orion Oyj B historical data?
Free Orion Oyj B historical data (last 10 years)
Browse or instantly download the last 10 years of Orion Oyj B daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ORNBV.HE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 100.4 |
| 2026-11-19 | 100.7 |
| 2026-11-18 | 101.4 |
| 2026-11-17 | 101.6 |
| 2026-11-16 | 103 |
| 2026-11-13 | 103 |
| 2026-11-12 | 102.7 |
| 2026-11-11 | 102.8 |
| 2026-11-10 | 101.9 |
| 2026-11-09 | 102.2 |
About this stock
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.